: EDITORIAL & COMMENTARY
| VOL. 16 | NO. 9
VIEW LATEST ISSUE
2020 Media KIt
Calendar of Events
Renew Your Subscription
Submit an Article
Research & Development
Business & Government Policy
Products & Services
CANCER RESEARCH NEWS:
CLICK HERE FOR WHAT'S NEW IN:
High Throughput Screening
Functional Genomic Screening
Editor’s Focus: Nearing year’s end and looking forward
Editor’s Focus: Alzheimer’s looms large in neuroscience
Editor’s Focus: Don’t rush a vaccine
Editor’s Focus: Cancer, COVID and change
Editor’s focus: The future of the face-to-face
Editor’s Focus: In this industry, we must stand strong against COVID-19
Editor’s Focus: Let’s talk about the C-word, shall we?
Editor’s Focus: Breaking down the outbreak
Editor’s Focus: Double helix, double bind
Editor’s Focus: Organic is often good for you
Editor’s Focus: An embarrassment of riches
Editor’s Focus: Artificial and essential, but still just a tool
Editor's focus: Struggling toward a prize we may never gain
Editor’s focus: Off-target effect from inactives?
Editor’s focus: The gene genie is out of the bottle
Editor's focus: Vaccines increasingly under perilous scrutiny
Editor’s focus: Shining light on depression?
Editor’s focus: Filling the voids
Editor's Focus: Your 2019 intelligence briefing
Editor’s focus: A ‘Q’ for ‘quality’ in Q1?
Editor’s focus: The balance between ROI and R&D
Editor’s focus: The struggle against schizophrenia
Editor’s focus: A ‘personalized’ problem in the public space
Editor’s Focus: Science isn’t always friendly, but it isn’t the enemy
Editor’s focus: Cancer should not be a ‘popularity contest’
Editor’s focus: Medicines going digital?
Editor’s focus: Navigating the gray areas
NIH needs more, not less
Editor’s focus: So much to share
Editor’s focus: Whose business is it, anyway?
Editor’s focus: What looks like outrage might be necessity
Blood will tell: Hematology in review
Dear readers, it’s time to meet Pete (if you haven’t already)
The treasures in our trove
Of a mind to decode the mind
Preclinical perils and clinical catastrophe
History in the making
Put your money where your science is
That crisp new CRISPR feeling
Recurring themes around these parts
‘21st Century Curse’ in the making?
An update on Cancer Moonshot efforts
A different sort of animal magnetism
Knowledge gaps and mistakes, and how both can lead to better things
Life sciences and pharma in ‘black and white’
Exposing that murderous ole FDA
The diseases are rare, corporate maneuvers are not; balance must be key
The ironic agonies of pain relief
Gene genie dilemma?
A cancer cavalcade for March
Get off the fence, FDA, and deal with generic labeling
Still no silver bullet, but progress continues against cancer
Looking back at 2015; walking boldly into 2016
Getting the cure where it needs to go
The price of doing drugs...er, drug development
At your ‘service’
Dog days of summer. Dog years of oncology?
M&As: Let’s serve ‘em up rare and juicy
We need to ‘C’ the big picture
21st Century Cures could arrive this century
Tech, tock; tech, tock…how long until we reveal all?
Out with the broad and in with the rare
Entering the 21st century…precisely?
Making a big deal of mergers
Clinical trials and tribulations
The business of reducing obesity
Much ado about Ebola
Editor's Focus: Topic of cancer
Keeping in touch with all of you
The word on ‘The Street’ is: Shopping
Preventing a preventive medicine backlash
Pharmas assemble! Up and away! Or something
Getting an infectious attitude
Too much of a therapeutic thing?
Warp speed ahead with the new DDNews
Publishers’ commentary: 10 years and expanding the pipeline
It's time now to sing out, though the story never ends
The gravity of the government shutdown’s impact on science
Ask, and science may receive
On which side of the pond is the grass greener?
First in Science: Fighting for research, funding and the American way
The many colors of sequestration
Cancer patients: The heart of the matter
Sherley v. Sebelius: Where do we go from here?
Three resolutions to improve your business in ‘13
A reflection on the old and in with the new
Pharma industry awaits impact of Obama’s second term
When the medium isn’t the message anymore
Genetic therapies? The heck, you say!
Public misconceptions about stem cells throw a wrinkle into scientific progress
Crohn’s a very personal disease
Michael J. Fox drives stem cell research efforts for Parkinson’s disease back to the future
Michigan university, lawmakers at impasse over hESCs
The little biotech that could
Falling short of filling unmet medical needs
Leave Paula Deen alone, y’all
Keeping our resolution to report the news
Out with the old, in with many new features to ddn
A news story is only as good as its sources
Announcing the ddn Cancer Research Portal: Your gateway to the latest oncology news, trends and resources
ddn’s ‘summer of stem cells’
Embryonic stem cell research: A Dickey-Wicker of a situation
Stem cell research: Sorting fact from fiction
Will open access open a Pandora’s box for scientific journals?
This just in: Stem cell research is a go
A message for Japan: ‘Ganbare’
ddn readers explain the ‘brain drain’
The brain drain: Degrees in vain?
A positive image never goes out of style
A new medium, a new message
Granny’s giggle gone too soon
When shareholders attack, it’s not just the news that suffers
ddn dissects current cancer craze
Our pharma, ‘tis of thee
We are all witnesses … to failure and success
Autism story hits close to home for ddn reporter
March marked by many mergers and acquisitions
Readers show support for Cleveland biotech hub
Cleveland: The next biotech hub?
Government’s watchful eye has pharma on guard
‘Twas the year of the M&A boom …
On your mark, get set … the race for the $1,000 genome heats up
Research Triangle Park or bust
‘Miles to go’ before Kennedy’s vision of healthcare reform is realized
Foreign governments feed biotechnology venture capital firms as U.S. appetite for bailouts wanes
Getting personal about personal genetics
Media’s treatment of Big Pharma can sometimes be a bitter pill to swallow
Lessons from AACR: Time is greatest obstacle in cancer treatment
Stop the presses: DDN expands online product
Biotechs seeing green this St. Patrick’s Day
Does anyone know what 2009 holds?
My first New Year’s resolution
Is pharma doing a good job of transforming?
Economic meltdown and where the money is
Emptying the drawer of the editorial mind
Few bargains in biotech acquisitions
How soon does 2015 seem to you?
A generic tale: Go east, young man!
Strange bedfellows: Bill Gates and Chairman Mao
De-valued dollar makes U.S. companies buyout targets
Of baseball and a cognitively-enhanced editor
Emptying the drawer of the editorial mind
BY ANY OTHER NAME
DARAs: an innovative approach to treating disease
Peace: A nod to things pharma does right
Protein Therapy vs. Gene Therapy
Microbicides: Stopping the spread of HIV/AIDS
Metabolomics: Clearing the logjam for biomarkers
The Process and the Ps
The side-effects of too many ads
Reflections on recent drug discovery trends
Reoviruses as cancer therapeutics
Twenty-five years of HIV/AIDS
Biomarkers: Busting blockbusters?
AT A PRICING CROSSROADS
Emptying the flotsam of the editorial mind
Solutions for the developing world
Finding time and money for the orphans
Dispelling discovery myths
Getting personal with biomarkers
MISSION: IMPOSSIBLE? Drugs can be safer, but never safe
Transformative industry event?
Will SFC challenge SMB for large-scale purifications?
The Yin and Yang of screening for gene functions
Pharma family trouble?
An "Absolute" Gamble
One patient, one vaccine
Vaccines for all
Is drug discovery moving too fast?
DNA for Peace
When big butterflies flap
The data integration saga: A QUESTION OF SEMANTICS?
Swing modestly, sweet legislators
Gene therapy and beyond: LEVERAGING LENTIVIRUSES
Getting it right: How does one go about correcting a correction?
ONE FLU: OVER THE CUCKOO’S NEST?
Thinking small: MINIATURIZATION MEANS MORE THAN LOW VOLUMES
HITTING THE TARGET
Raising the ethical bar: Advancing the stem cell debate
Activity and novelty: Managing risk in drug discovery
A YEAR OF CHANGE
Hopped up on hyperbole
Beyond gene expression: Promising new uses for microarrays
It’s a numbers game: Is it an industry of biology and chemistry or ones and zeros?
ONE MAN’S JUNK: Mother Nature’s little helper
THE DATA DELUGE: Looking to hardware for high-performance computing solutions
Hungry for more content? There’s plenty at drugdiscoverynews.com
From our e-Newsletter... In a class of its own
Bogged down in biomarker details: To solve bigger problems, we need to look at the bigger picture
Three things to ponder: Off loading the flotsam of the editorial mind
Two steps forward, one back: Will Phase 0 or microdosing save drug discovery?
Can't stem this tide
Drugs and Diagnostics: Two sides of one process?
Business, as usual
Speed and time are of the essence
Need business news? We’ll deliver it.
News moves the market
Pharma industry pow-wows: Waiting on the smoke signal
Cannabinoid research speeding up its pace
PRINT CURRENT PAGE
SEND THIS PAGE TO A COLLEAGUE
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 | Fax: 705-528-0270
Submit News Release
Terms & Conditions
© Copyright 2020 Old River Publications LLC. All righs reserved. | Web site managed and designed by